Home | Welcome to Contract Pharma   
Last Updated Friday, May 29 2015


Financial Report: Charles River Labs

Published May 1, 2014
Charles River Labs
1Q Revenues: $299.4 million (+3%)

1Q Earnings: $32.4 million (+26%)

Comments: RMS segment sales were $185.6 million in the quarter, up 2%, with growth in the Endotoxin and Microbial Detection (EMD) business. Preclinical Services (PCS) segment sales were $113.8 million, up 5% driven by continued demand from mid-tier biotechnology clients.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On